00:59 , Feb 7, 2019 |  BioCentury  |  Finance

Chinese Innovation: Threat or Opportunity?

Mounting techno-protectionism in response to China’s innovation drive seems destined to sap U.S. scientific leadership and entrepreneurial vigor, driving talent and capital to Europe and Asia. Biotech offers a compelling alternative to the current trend,...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:05 , Jan 4, 2019 |  BC Innovations  |  Translation in Brief

Testing reflex vs. reality in pain

A Dana-Farber Cancer Institute team has challenged the assumptions behind standard pain models, suggesting their use contributes to poor clinical translation of pain therapies and advocating adoption of behavioral tests reflecting pain sensation instead of...
00:22 , Dec 22, 2018 |  BioCentury  |  Finance

Venture surge

Venture capital investments in the life sciences surged to more than $20 billion worldwide in 2018, with VCs increasingly concentrating their disbursements in nine-digit megarounds, some of which preceded IPOs later in the year. Through...
18:35 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Full data for Aimmune's peanut allergy therapy published in NEJM

The New England Journal of Medicine published full data from the Phase III PALISADE trial of peanut allergy therapy AR101 from Aimmune Therapeutics Inc. (NASDAQ:AIMT), including detailed safety showing a higher rate of rescue epinephrine...
00:39 , Nov 20, 2018 |  BC Extra  |  Clinical News

Aimmune down on safety concerns for peanut allergy therapy

Aimmune Therapeutics Inc. (NASDAQ:AIMT) was off $3.33 (11%) to $26.29 on Monday after the New England Journal of Medicine published full data from the Phase III PALISADE trial of the company's peanut allergy therapy AR101,...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
15:08 , Nov 15, 2018 |  BioCentury  |  Politics, Policy & Law

Requiring Drug Prices in TV Ads Violates First Amendment

Drug companies, which have learned to live with advertisements calling out a litany of possible side effects for their drugs, may want to take a couple of aspirin. The recent announcement by CMS that it...
01:43 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Biopharma may have to wait for Brexit details

With U.K. and EU governments reaching a draft Brexit deal on Tuesday, the future of drug regulation in the U.K. and the country’s participation in EU science programs may take months to hammer out even...